Editor Note: For more information about this release, please scroll to bottom.
LONDON, July 7, 2014 /PRNewswire/ --
On Thursday, July 03, 2014, the NASDAQ Composite ended at 4,485.93, up 0.63%, the Dow Jones Industrial Average advanced 0.54%, to finish the day at 17,068.26, and the S&P 500 closed at 1,985.44, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index also advancing 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), InterMune Inc. (NASDAQ:ITMN), Cytokinetics Inc. (NASDAQ:CYTK) and Biogen Idec Inc. (NASDAQ:BIIB). Free technical research on ALXN, ITMN, CYTK and BIIB can be downloaded upon signing up at:
On Thursday, shares in Alexion Pharmaceuticals Inc. fluctuated between $162.49 and $165.96 before ending the session 0.01% lower at $164.21. Alexion Pharmaceuticals Inc.'s stock reported a trading volume of 0.72 million shares, below its three months average volume of 1.42 million shares. Shares of the company traded at a PE ratio of 91.96. Alexion Pharmaceuticals Inc.'s shares have advanced 5.09% in the previous three trading sessions, 15.24% in the last three months and 23.57% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $161.11 and $144.25, respectively. Moreover, shares of the company have a Relative Strength Index (RSI) of 54.20. Sign up today to read free research on ALXN at:
InterMune Inc.'s stock edged 0.66% higher, to close the day at $44.44. The stock recorded a trading volume of 0.87 million shares, much below its three months average volume of 2.34 million shares. The stock oscillated between $43.88 and $44.99 during the session. Over the last one month and over the past three months, InterMune Inc.'s shares have surged 8.02% and 45.23%, respectively. Further, the stock has gained 201.70% since the start of this year. The stock is trading above its 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $39.46 is greater than its 200-day moving average of $24.15. Additionally, the stock has an RSI of 61.14. Sign up today to read free research on ITMN at:
On Thursday, shares in Cytokinetics Inc. recorded a trading volume of 0.24 million shares, lower than its three months average volume of 1.34 million shares. The stock ended the day at $4.90, which was 0.62% above its previous day's closing of $4.87, and registered an intraday range of $4.81 and $4.96. Cytokinetics Inc.'s shares have advanced 2.51% in the previous three trading sessions and 2.08% in the last one month. However, the stock has lost 24.62% since the beginning of this year. The stock is trading above its 50-day moving average of $4.87, while the 50-day moving average is below Cytokinetics Inc.'s 200-day moving average of $7.21. Furthermore, shares of the company have an RSI of 48.16. Sign up today to read free research on CYTK at:
Biogen Idec Inc.'s stock finished the Thursday's session 0.05% higher at $331.15. A total of 0.70 million shares were traded, which was below its three months average volume of 1.37 million shares. The stock moved between $328.23 and $332.93 during the session. Over the last three trading sessions and the previous three months, Biogen Idec Inc.'s shares have gained 5.02% and 14.88%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 18.45%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $304.77 is greater than its 200-day moving average of $290.32. Biogen Idec Inc.'s stock traded at a PE ratio of 41.00 and has an RSI of 68.09. Sign up today to read free research on BIIB at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.